>>> Novo Nordisk A/S B Deputy CEO: Sees annual rev growth of 10% over next 10-20 Novo Nordisk A/S B Deputy CEO: Sees annual rev growth of 10% over next 10-20 years - press - Rival will struggle to keep up with new GLP-1 diabetes pill --> could weight on Sanofi